Browse the evidence

Retatrutide (4-12 mg weekly) produces early, sustained changes in appetite and eating behaviors (reduced hunger, increased satiety, smaller portions) within 8 weeks, leading to significant weight loss and improved physical/emotional well-being in adults with obesity.

If you have obesity or overweight with health complications, retatrutide (4-12mg weekly) significantly reduces hunger and increases fullness within weeks, leading to substantial weight loss (up to 24%) and improved energy/mobility. It addresses the biological barriers to lifestyle changes that often cause failure with diet/exercise alone. Expect some frustration if results are slower than hoped or side effects occur, but the behavioral shift in eating is a key benefit.

In individuals with Type 2 Diabetes Mellitus, a 15-minute post-meal walk at ~60% VO2peak significantly reduces daily insulin exposure (AUC) and post-prandial glucose/insulin spikes, whereas an 8-hour time-restricted eating (TRE) window alone does not significantly alter total daily blood glucose compared to a 12-hour window.

If you have Type 2 Diabetes, focus on taking a 15-minute walk after your main meals rather than strictly restricting your eating window to 8 hours for immediate glucose control. This specific timing of light-to-moderate intensity walking significantly lowers insulin requirements and reduces post-meal blood sugar spikes, which helps manage daily glycemic variability.

Semaglutide demonstrates the greatest mean reduction in body weight among GLP-1RAs in psychiatric populations, significantly outperforming placebo and showing superior efficacy to liraglutide and exenatide in network meta-analysis.

Among GLP-1 medications, semaglutide (oral) appears to produce the most significant weight loss in patients with psychiatric conditions, averaging over 6 kg (13 lbs) loss. It is more effective than liraglutide or exenatide in this group. However, data is limited to one study, so discuss availability and cost with your provider.

Dual GLP-1R/GIPR agonists (e.g., tirzepatide) provide superior glycemic control and weight reduction compared to single-target incretin agonists.

If you have type 2 diabetes or obesity, dual-acting medications like tirzepatide may offer better weight loss and blood sugar control than older single-acting drugs. These are injectable medications that mimic gut hormones to reduce appetite and improve insulin function. Consult a doctor to see if this advanced therapy is appropriate for your specific health profile.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce clinically significant weight loss (15-21%) and improve comorbidities, but require long-term continuous use to maintain benefits.

GLP-1 medications like semaglutide and tirzepatide are highly effective for significant weight loss (15-21%) and improving health conditions like diabetes and heart disease. However, they are not cosmetic shortcuts. You must commit to long-term use, as stopping the medication usually leads to regaining the weight. Work with your doctor to manage side effects and adjust other medications as you lose weight.

GLP-1/GIP dual receptor agonists (e.g., tirzepatide) produce significantly greater weight loss than GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and non-GLP-1 agents (e.g., orlistat, phentermine/topiramate) in weight management trials.

If you are struggling with obesity, GLP-1/GIP dual agonists like tirzepatide are currently the most effective pharmacological option for weight loss, significantly outperforming older medications and even single-target GLP-1 agonists. This comes with the need for weekly injections (or oral alternatives) and careful dose escalation to manage side effects.

GLP-1 receptor agonists (semaglutide 2.4 mg weekly) and dual incretin agonists (tirzepatide) significantly reduce hepatic steatosis and improve or resolve steatohepatitis (MASH) in patients with MASLD, primarily through sustained weight loss and improved insulin sensitivity.

If you have fatty liver disease linked to metabolic issues, GLP-1 medications like semaglutide are currently the most effective pharmacological tool to reverse liver inflammation and fat. They work by targeting the root metabolic causes rather than just the liver itself. Consult a doctor to see if you qualify for these treatments, especially if lifestyle changes alone haven't resolved your liver health markers.

Tirzepatide, a dual GLP-1/GIP receptor agonist, provides greater HbA1c reduction and weight loss compared to semaglutide 1 mg in patients with Type 2 Diabetes.

If you need significant weight loss and blood sugar control, ask your doctor about tirzepatide. It may work better than older GLP-1 drugs like semaglutide 1 mg, but it is more expensive.

Semaglutide (2.4 mg) is the most cost-effective and clinically effective pharmacological intervention for obesity treatment compared to other FDA-approved medications and lifestyle interventions.

For adults with obesity, Semaglutide (2.4 mg weekly) combined with diet and exercise is currently the most effective and economically favorable medication option available, outperforming older drugs like Orlistat in most healthcare settings.

Phenotype-guided treatment selection (matching drug mechanism to obesity subtype like 'hungry brain' or 'slow burn') results in significantly greater weight loss compared to standard care.

Ask your doctor about your obesity phenotype (e.g., 'hungry brain', 'slow burn'). Matching your medication to your specific metabolic or behavioral drivers can nearly double your weight loss success compared to standard treatment approaches.

Tirzepatide (TZP) produces significantly greater weight loss than semaglutide (SEM) in patients with rheumatic and musculoskeletal diseases (RMDs), with TZP users losing 8.2% of body weight compared to 5.8% for SEM users at 12 months.

If you have a rheumatic condition and are using GLP-1 medications, Tirzepatide is associated with greater weight loss than Semaglutide. In this large study, Tirzepatide users lost 8.2% of their body weight at 12 months, compared to 5.8% for Semaglutide users. This benefit was observed even in patients with mobility limitations, suggesting that pharmacological intervention can overcome some barriers to weight loss in this population.

Protein and essential amino acid (EAA) supplementation promotes measurable muscle hypertrophy (via ultrasound/MRI) only when daily intake is below 1.6 g/kg/day or per-meal leucine is below 2–3 g; benefits plateau once these thresholds are met.

If you already eat enough protein (around 1.6g per kg of body weight) or get enough leucine per meal (2-3g), adding more protein powder will not make your muscles grow bigger. Focus on hitting that baseline first; extra protein is wasted for hypertrophy purposes.

Incretin receptor agonists (GLP-1RA, dual/triple agonists) and SGLT2 inhibitors reduce the risk of progression to type 2 diabetes and improve cardiovascular outcomes in patients with prediabetes, primarily through weight loss and reduction of visceral ectopic fat.

If you have prediabetes along with obesity, heart failure, or kidney disease, your doctor may consider newer medications like GLP-1 agonists (e.g., semaglutide) or SGLT2 inhibitors. These drugs help with weight loss and reduce cardiovascular risk. They are not yet first-line for all prediabetes patients due to cost and lack of formal indications, but they can be very effective for high-risk individuals.

Intensive lifestyle interventions (ILIs) targeting fat reduction (specifically visceral and body fat mass) significantly improve complete remission rates in overweight patients undergoing fertility-sparing treatment for endometrial cancer and intraepithelial neoplasia.

For overweight patients undergoing fertility-sparing treatment for endometrial precancer, intensive lifestyle changes focusing on fat loss (not just scale weight) significantly improve remission rates. This involves a caloric deficit, daily moderate aerobic exercise, and resistance training to protect muscle mass. Aim for a modest ~3% weight loss, as excessive loss may reduce efficacy by depleting muscle.

Low-carbohydrate diets can induce remission of type 2 diabetes, with clinical trials showing >50% remission rates in some studies.

If you have type 2 diabetes, a ketogenic diet (20-50g carbs/day) can potentially lead to remission. Work with your doctor to monitor blood sugar and adjust medications, as many patients reduce or stop medications within weeks.

Obesity causes secondary hormonal changes (elevated TSH, insulin/leptin resistance) that mimic hypothyroidism; weight loss alone can normalize these hormone levels without thyroid medication.

If you are obese and have slightly high TSH, it might be because of your weight, not a broken thyroid. Losing weight can often fix these hormone levels without medication. Ask your doctor if your thyroid issue is 'secondary' to obesity.

GLP-1 receptor agonists (e.g., tirzepatide) and bariatric surgery are highly effective for weight loss in patients with thyroid disease and should be considered when behavioral therapy fails, as they do not increase thyroid cancer risk in non-MTC patients.

If diet and exercise aren't enough, GLP-1 drugs or surgery are safe and effective options even if you have thyroid disease (unless you have a specific family history of thyroid cancer). These treatments cause significant weight loss (5-20%+) and improve cardiovascular health.

Cagrilintide-Semaglutide (CagriSema) produces superior weight loss and metabolic improvements compared to monotherapies and placebo in adults with overweight or obesity, with or without type 2 diabetes.

CagriSema is a potent, non-surgical weight loss option that significantly outperforms current GLP-1 monotherapies. It requires weekly (implied) injections and lifestyle changes. Expect transient GI side effects that usually subside. It is suitable for those with BMI ≥30 (or ≥27 with comorbidities), including those with T2D.

Time-restricted eating (TRE) significantly reduces body weight and fasting insulin levels in overweight and obese women compared to control groups, without negatively affecting fat-free or lean body mass.

If you are overweight or obese, try restricting your eating window to 8-10 hours a day (e.g., 10 AM to 6 PM). This approach has been shown to help women lose weight and improve insulin sensitivity without losing muscle mass, and it is often easier to stick to than strict calorie counting.

Lactobacillus sp. probiotic supplementation significantly reduces body mass index, body weight, waist and hip circumference, and visceral/subcutaneous fat mass in non-comorbid obese individuals compared to placebo.

If you are obese without other major health conditions, adding a Lactobacillus probiotic (doses ranging from 1 million to 50 billion CFU daily) to your routine may help reduce body weight, BMI, and waist circumference. The effect is modest but statistically significant, particularly when taken for at least 12 weeks. It is not a magic bullet but may support other lifestyle changes.

In adults with obesity without diabetes, tirzepatide produces significantly greater weight loss and cardiometabolic improvements than semaglutide over 6 months, even when semaglutide patients receive higher maintenance doses.

If you are choosing between tirzepatide and semaglutide for obesity management without diabetes, tirzepatide offers greater weight loss and better cardiometabolic improvements over 6 months. This advantage holds true even if you are on a higher maintenance dose of semaglutide than the typical tirzepatide dose. Consult your doctor to determine which medication aligns best with your health profile and insurance coverage.

Six months of intermittent fasting (2-3 non-consecutive days of vegetable-only fasting per week) significantly reduces body weight, body fat, and improves lipid profiles (LDL-C, non-HDL-C, triglycerides) in middle-aged adults with overweight, without significantly affecting blood pressure, fasting glucose, or inflammatory markers.

If you are overweight and middle-aged, trying intermittent fasting 2-3 days a week with a vegetable-only diet on those days can significantly improve your weight and cholesterol levels without needing to change your diet on other days. This approach is well-tolerated and offers specific metabolic benefits beyond just eating less.

Flexible time-restricted eating combined with aerobic exercise improves insulin resistance (HOMA-IR) and insulin levels more effectively than either intervention alone.

To improve your insulin sensitivity, combining an 8-hour eating window with regular moderate aerobic exercise is more effective than doing either one alone. This approach helps lower insulin levels and improve insulin resistance markers more significantly than diet or exercise in isolation.

Semaglutide 2.4 mg weekly produces substantial and durable weight loss (10-15%) in adults with overweight or obesity through central appetite suppression, delayed gastric emptying, and improved glucose homeostasis.

If you have obesity, semaglutide 2.4 mg taken once weekly is a highly effective treatment for significant weight loss (10-15%). It works by reducing appetite and slowing digestion. Start with a low dose to minimize stomach upset, which usually improves over time. It is a long-term commitment, not a quick fix.